Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura

Muscle and Nerve

Volumn 38, Issue 2, 2008, Pages 1076-1077

  Benedetti, Luana ^a   Franciotta, Diego ^b   Beronio, Alessandro ^c   Cadenotti, Luigi ^c   Gobbi, Marco ^a   Mancardi, Giovanni Luigi ^a   Schenone, Angelo ^a   Tartaglione, Antonio ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PREDNISONE; RITUXIMAB;

ADULT; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LETTER; MALE; MOTOR NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACTION POTENTIALS; ANTIBODIES, MONOCLONAL; ELECTRIC STIMULATION; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEURAL CONDUCTION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES;

EID: 49449113252     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21073     Document Type: Letter

References (8)

1. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systemic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
2. British Committee for Standards in Haematology General Haematology Task Force. Guidelines in the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120: 574-596.
3. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007;35:66-69.
4. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50: 195-201.
5. Kleyweg RP, van der Mechè FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14: 1103-1109.
6. Knecht H, Baumberger M, Tobon A, Steck A. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004; 63:730-732.
7. Merkies I, Schmitz P, Van Der Mech' F, Van Doorn P, for the Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology 2000;54:943-949.
8. Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V, et al. Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006;34:571-572.